Modafinil, Sleep Architecture and Cocaine Relapse

Conditions

Cocaine Dependence

Trial Phase

Trial Purpose and Description

Trial Purpose

The medication modafinil has been shown to reduce cocaine use in some cocaine users. The investigators have shown that modafinil taken in the morning improves sleep in chronic cocaine users. The investigators hypothesize that the beneficial effects of modafinil in reducing cocaine use may be related to specific effects modafinil has on sleep. This study will measure sleep and cocaine use in cocaine dependent persons who are trying to stop using cocaine, and will test the connection between modafinil's effects on sleep and cocaine use.


Participation Guidelines

Age:
25 Years - 50 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria:

  • 25-50 years of age
  • voluntary, written, informed consent
  • seeking but not currently enrolled in treatment for cocaine use
  • self-reported, current use of cocaine by smoked or intravenous route at least one
    time each week in the past month, with =1g used within a single 24-hour period and
    =3g used in the month
  • positive urine test for cocaine (benzoylecognine) at the time of screening and study
    start
  • dependence on cocaine in the past year as measured by a score = 3 on the Severity of
    Dependence Scale(Kaye and Darke, 2002)
  • chronic use in the past year as determined by self-reported use in at least 9 of the
    past 12 months
  • lifetime diagnosis of cocaine dependence with a duration of at least 2 years as
    determined by the Structured Clinical Interview for DSM-IV (SCID).

Exclusion Criteria:

  • evidence of any neurological condition or a chronic medical condition including
    diabetes, cardiovascular disease or history of cardiac problems, HIV-seropositivity,
    liver disease, hypertension, asthma requiring daily medication, dementia, movement
    disorder, history of head trauma with loss of consciousness, sleep apnea, narcolepsy,
    restless leg syndrome, periodic limb movement disorder, REM sleep disorder,
    pharmacological treatment for insomnia of any type within the past 6 months,
    glaucoma, severe respiratory insufficiency, seizure disorder, or if in the past three
    months they have taken any medications that affect sleep, or are currently taking any
    regularly dosed prescription medication or any prn medication that is used on average
    more than 1x/week
  • evidence of chronic sleep disorder including sleep apnea, narcolepsy, periodic limb
    movement disorder, restless leg syndrome as determined by medical history, Sleep
    Disorders Questionnaire(Douglass, 1994), or by polysomnography (following enrollment)
  • current dependence on any drugs other than cocaine or nicotine or lifetime dependence
    on alcohol, benzodiazepines, or opiates, or any non-substance related Axis I disorder
    as determined by SCID
  • current use of alcohol in excess of 3x/week AND 21 standard drinks/week in the past
    month or non-zero breathalyzer at screening or study start
  • current use of cannabis in the past month
  • positive urine toxicology test for opiates, methadone, amphetamines, barbiturates,
    benzodiazepines, PCP, methaquolone, and propoxyphene at the time of screening or
    positive test for any of those listed plus cannabis at the time of study start
  • pregnancy as determined by serum 7-HCG at screening or lactating per report
  • females: unwillingness to use barrier contraceptives during sexual intercourse for
    the duration of the study
  • known hypersensitivity to modafinil.
Sponsor:
National Institute on Drug Abuse
Yale University
Dates:
04/10/2010
Last Updated:
Study HIC#:
0911005989